Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Question Of Omecamtiv, Sotorasib Filing Plans Unanswered

 
• By Mandy Jackson
  
Abstract mash line and point Question mark. Business illustration. Polygonal low poly
Amgen left questions unanswered regarding sotorasib, omecamtiv and tezepelumab

More from Earnings

More from Business